ArticleMedical oncology (Northwood, London, England)2012
HLA class-II allele frequencies in Turkish breast cancer patients.
Article in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 11 citations in OpenAlex.
- Human Leukocyte Antigen Alleles (HLA-A, HLA-B, and HLA-DRB1) are associated with Acute Lymphoblastic Leukemia (ALL) : A Case-Control Study in a Sample of Iranian Population.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Carriage of HLA-DRB1*11 and 1*12 alleles and risk factors in patients with breast cancer in Burkina Faso.Open life sciences · 2021Article
- Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice.PloS one · 2019Article
- HLA alleles in breast cancer.Pathology oncology research : POR · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Class-II human leukocyte antigens (HLA) present tumor antigenic peptides on the cell surface in order to be recognized by T lymphocytes. Thereby, these molecules can play an important role in the immune response to breast cancer tumor antigens. The aim of this study was to determine the relation between breast cancer and HLA class-II alleles in Turkey. The study groups consisted of 69 breast cancer patients and 45 healthy controls. Typing of HLA-DRB1 and HLA-DQB1 from DNA samples was performed by Sequence Specific Oligonucletide Hybridisation. Significant negative correlations were observed between HLA-DRB1 03 and HLA-DQB1 02 alleles and breast cancer (p1 = 0.019; p2 = 0.019) and also between HLA-DQB1 02 allele and postmenopausal breast cancer (P = 0.022) and c-erb-B2 positivity (P = 0.038). Furthermore, there was a significant positive correlation between HLA-DRB1 13 and HLA-DQB1 06 alleles and progesteron receptor positivity (p1 = 0.012; p2 = 0.001); and a significant negative correlation between HLA-DQB1 03 allele and progesteron receptor positivity (P = 0.009) in breast cancer. Additionally, another significant positive correlation was seen between HLA-DRB1 04 allele and c-erb-B2 positivity (P = 0.036). As a result, while HLA-DRB1 03, HLA-DQB1 02, HLA-DRB1 13, and HLA-DQB1 06 alleles were found to be involved in protectiveness against breast cancer and good prognosis; HLA-DQB1 03 and HLA-DRB1 04 alleles were found to be involved in poor prognosis. In conclusion, by determining allele types showing predisposition to breast cancer, a systematical screening and follow up systems can be developed for patients who are at high risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.